The US government has approved a $2 billion drug to treat people with keratoconus, a rare and serious condition that results from the breakdown of the hair on the back of the neck.
But as it stands, it’s only available through the Veterans Affairs Medical Centers Pharmacy network.
The FDA announced in December that it had approved the treatment for patients with keratinosis and other keratomas.
The FDA says the drug can also treat keratosis, a condition that causes the hair loss.
But the FDA has not said when the FDA will begin taking patients off the drug.
But, the agency said that the approval of the drug is conditional on the VA providing data showing that the VA can manage the treatment with a minimum of disruption.
In November, the FDA also approved a drug to control psoriasis, a disease that causes long-term hair loss and can lead to hair loss in the neck region.
The drug will be available through VA’s Pharmacy Network.
The DEA approved a new drug, an alpha-lipoic acid treatment, in January for patients who have type 2 diabetes and are taking insulin.
As the FDA and DEA have been able to approve new medications without significant disruption, the drug could be in the pipeline for a while, but until the agency announces the date for when to begin taking the drug, the public should be very cautious.
This article is part of a series called “What’s on the table for the FDA in November” The full article can be found here.
Follow Ryan Saavedra on Twitter @salavaredra